BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

903 related articles for article (PubMed ID: 25380967)

  • 1. PDGF receptor alpha inhibition induces apoptosis in glioblastoma cancer stem cells refractory to anti-Notch and anti-EGFR treatment.
    Cenciarelli C; Marei HE; Zonfrillo M; Pierimarchi P; Paldino E; Casalbore P; Felsani A; Vescovi AL; Maira G; Mangiola A
    Mol Cancer; 2014 Nov; 13():247. PubMed ID: 25380967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The interference of Notch1 target Hes1 affects cell growth, differentiation and invasiveness of glioblastoma stem cells through modulation of multiple oncogenic targets.
    Cenciarelli C; Marei HE; Zonfrillo M; Casalbore P; Felsani A; Giannetti S; Trevisi G; Althani A; Mangiola A
    Oncotarget; 2017 Mar; 8(11):17873-17886. PubMed ID: 28157712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PDGFRα depletion attenuates glioblastoma stem cells features by modulation of STAT3, RB1 and multiple oncogenic signals.
    Cenciarelli C; Marei HE; Felsani A; Casalbore P; Sica G; Puglisi MA; Cameron AJ; Olivi A; Mangiola A
    Oncotarget; 2016 Aug; 7(33):53047-53063. PubMed ID: 27344175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling.
    Chakravarti A; Loeffler JS; Dyson NJ
    Cancer Res; 2002 Jan; 62(1):200-7. PubMed ID: 11782378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
    Xie M; He CS; Wei SH; Zhang L
    Eur J Cancer; 2013 Nov; 49(16):3559-72. PubMed ID: 23916913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma.
    Ashizawa T; Miyata H; Iizuka A; Komiyama M; Oshita C; Kume A; Nogami M; Yagoto M; Ito I; Oishi T; Watanabe R; Mitsuya K; Matsuno K; Furuya T; Okawara T; Otsuka M; Ogo N; Asai A; Nakasu Y; Yamaguchi K; Akiyama Y
    Int J Oncol; 2013 Jul; 43(1):219-27. PubMed ID: 23612755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arsenic trioxide sensitizes glioblastoma to a myc inhibitor.
    Yoshimura Y; Shiino A; Muraki K; Fukami T; Yamada S; Satow T; Fukuda M; Saiki M; Hojo M; Miyamoto S; Onishi N; Saya H; Inubushi T; Nozaki K; Tanigaki K
    PLoS One; 2015; 10(6):e0128288. PubMed ID: 26038891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
    Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L
    Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential role of EGF and BFGF in human GBM-TIC proliferation: relationship to EGFR-tyrosine kinase inhibitor sensibility.
    Bajetto A; Porcile C; Pattarozzi A; Scotti L; Aceto A; Daga A; Barbieri F; Florio T
    J Biol Regul Homeost Agents; 2013; 27(1):143-54. PubMed ID: 23489694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated expression of Notch-1 and EGFR induced apoptosis in glioblastoma multiforme patients.
    Xing ZY; Sun LG; Guo WJ
    Clin Neurol Neurosurg; 2015 Apr; 131():54-8. PubMed ID: 25704190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide.
    Ning S; Knox SJ
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):197-203. PubMed ID: 15337556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting PDGFRα-activated glioblastoma through specific inhibition of SHP-2-mediated signaling.
    Sang Y; Hou Y; Cheng R; Zheng L; Alvarez AA; Hu B; Cheng SY; Zhang W; Li Y; Feng H
    Neuro Oncol; 2019 Nov; 21(11):1423-1435. PubMed ID: 31232447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting of EGFR increase anti-cancer effects of arsenic trioxide: Promising treatment for glioblastoma multiform.
    Mesbahi Y; Zekri A; Ahmadian S; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
    Eur J Pharmacol; 2018 Feb; 820():274-285. PubMed ID: 29274334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of F90, an epidermal growth factor receptor tyrosine kinase inhibitor, on glioblastoma cell line SHG-44.
    Liu FJ; Gui SB; Li CZ; Sun ZL; Zhang YZ
    Chin Med J (Engl); 2008 Sep; 121(17):1702-6. PubMed ID: 19024103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.
    Zhang M; Kleber S; Röhrich M; Timke C; Han N; Tuettenberg J; Martin-Villalba A; Debus J; Peschke P; Wirkner U; Lahn M; Huber PE
    Cancer Res; 2011 Dec; 71(23):7155-67. PubMed ID: 22006998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the insulin-like growth factor 1 receptor by CHM-1 blocks proliferation of glioblastoma multiforme cells.
    Lin YC; Hou SC; Hung CM; Lin JN; Chen WC; Ho CT; Kuo SC; Way TD
    Chem Biol Interact; 2015 Apr; 231():119-26. PubMed ID: 25643584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dedifferentiation of patient-derived glioblastoma multiforme cell lines results in a cancer stem cell-like state with mitogen-independent growth.
    Olmez I; Shen W; McDonald H; Ozpolat B
    J Cell Mol Med; 2015 Jun; 19(6):1262-72. PubMed ID: 25787115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
    Wu M; Yuan Y; Pan YY; Zhang Y
    Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antagonist activity of the antipsychotic drug lithium chloride and the antileukemic drug imatinib mesylate during glioblastoma treatment in vitro.
    Aras Y; Erguven M; Aktas E; Yazihan N; Bilir A
    Neurol Res; 2016 Sep; 38(9):766-74. PubMed ID: 27367429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.